For patients and therapists, believing in the benefits state-of-the-art robotic medical devices bring to the table is one thing. But having your beliefs incorporated into the official practice guidelines by associations of experts and authorities in the field is something entirely different.
Yet this is exactly what is happening. The newest Guidelines for Adult Stroke Rehabilitation and Recovery from the American Heart Association/American Stroke Association (AHA/ASA) were recently published. The following statements can be found in this important publication[1]:
Robot-assisted movement training, to improve motor function and mobility after stroke in combination with conventional therapy, is beneficial for patients.
Robot-assisted gait training is specifically beneficial for patients who are non-ambulatory or have low ambulatory ability early after stroke.
Combining robot-assisted gait training with virtual reality can further be beneficial for the improvement of gait.
Scientific studies back the statements the AHA/ASA are putting forth. The end goal is to provide a synopsis of best clinical practices in the rehabilitative care of adults recovering from stroke; and Hocoma fully agrees with these statements and recommendations.
Hocoma, the world leader in developing advanced medical solutions and inventor of the most-trusted robotic gait trainer, firmly believes their Lokomat helps. On one hand, patients train more accurately and more intensively, and on the other, therapists simplify their workflow and assessment of patient progress. And the fact that these beliefs are not only being embraced by the institutions in the field, but are also supported by scientific evidence, is an important step forward for rehabilitation therapy.
[1] References:
"Guidelines for Adult Stroke Rehabilitation and Recovery" http://stroke.ahajournals.org/content/early/2016/05/04/STR.0000000000000098.full.pdf+html?sid=7f40d463-5fde-43bd-aa07-ea26dc5a2fb1
"First-Ever AHA/ASA Stroke Rehab Guidelines Support IRFs, Interprofessional Approaches" http://www.apta.org/PTinMotion/News/2016/5/10/StrokeRehabPracticeGuidelines/
Product Disclaimer
All Hocoma products are medical devices and must be used in strict adherence to the User Manual; failure to do so may result in serious personal injury. It is strongly recommended that you regularly consult Hocoma’s website (www.hocoma.com/legalnotes) for the latest available information. Please contact Hocoma in case of any questions.
Use only under the supervision of qualified medical personnel. However, certain Hocoma products are marketed for home use and must be strictly used according to the recommendations of your medical care provider who is knowledgeable about your specific needs. Consult the User Manual and Hocoma’s website (www.hocoma.com/legalnotes) for appropriate product designation. Failure to obtain and follow the recommendations of your medical care provider may result in serious personal injury.
This information provides details about medical products which may not be available in all countries and may not have received approval or market clearance by all governmental regulatory bodies throughout the world. Nothing herein should be construed as a solicitation or promotion of any product or of an indication of any specific use for any product which is not authorized by the laws and regulations of the country where the reader of this information resides.
Yet this is exactly what is happening. The newest Guidelines for Adult Stroke Rehabilitation and Recovery from the American Heart Association/American Stroke Association (AHA/ASA) were recently published. The following statements can be found in this important publication[1]:
Robot-assisted movement training, to improve motor function and mobility after stroke in combination with conventional therapy, is beneficial for patients.
Robot-assisted gait training is specifically beneficial for patients who are non-ambulatory or have low ambulatory ability early after stroke.
Combining robot-assisted gait training with virtual reality can further be beneficial for the improvement of gait.
Scientific studies back the statements the AHA/ASA are putting forth. The end goal is to provide a synopsis of best clinical practices in the rehabilitative care of adults recovering from stroke; and Hocoma fully agrees with these statements and recommendations.
Hocoma, the world leader in developing advanced medical solutions and inventor of the most-trusted robotic gait trainer, firmly believes their Lokomat helps. On one hand, patients train more accurately and more intensively, and on the other, therapists simplify their workflow and assessment of patient progress. And the fact that these beliefs are not only being embraced by the institutions in the field, but are also supported by scientific evidence, is an important step forward for rehabilitation therapy.
[1] References:
"Guidelines for Adult Stroke Rehabilitation and Recovery" http://stroke.ahajournals.org/content/early/2016/05/04/STR.0000000000000098.full.pdf+html?sid=7f40d463-5fde-43bd-aa07-ea26dc5a2fb1
"First-Ever AHA/ASA Stroke Rehab Guidelines Support IRFs, Interprofessional Approaches" http://www.apta.org/PTinMotion/News/2016/5/10/StrokeRehabPracticeGuidelines/
Product Disclaimer
All Hocoma products are medical devices and must be used in strict adherence to the User Manual; failure to do so may result in serious personal injury. It is strongly recommended that you regularly consult Hocoma’s website (www.hocoma.com/legalnotes) for the latest available information. Please contact Hocoma in case of any questions.
Use only under the supervision of qualified medical personnel. However, certain Hocoma products are marketed for home use and must be strictly used according to the recommendations of your medical care provider who is knowledgeable about your specific needs. Consult the User Manual and Hocoma’s website (www.hocoma.com/legalnotes) for appropriate product designation. Failure to obtain and follow the recommendations of your medical care provider may result in serious personal injury.
This information provides details about medical products which may not be available in all countries and may not have received approval or market clearance by all governmental regulatory bodies throughout the world. Nothing herein should be construed as a solicitation or promotion of any product or of an indication of any specific use for any product which is not authorized by the laws and regulations of the country where the reader of this information resides.
